Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Daily ultrasound could keep heart failure patients out of the hospital

NCT ID NCT02892227

Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether daily bedside ultrasound scans help doctors better adjust treatment for people hospitalized with acute heart failure. The goal was to see if this approach reduces the number of patients readmitted within 30 days. The study involved 250 adults with heart failure and low heart function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

250 people

The number who actually took part.

Started

Nov 2016

Finished

Jun 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The patient or his representative must be given free and informed consent and signed consent. * The patient must be affiliated or beneficiary of a health insurance plan. * The patient is available for a follow-up 6 months. * The patient is of age or older (\>) 18. * Patients hospitalized for acute heart failure who received at least 40mg of furosemide IV. * Patient with impaired LVEF \<50%. * Patient with Nt-proBNP values\> 1200pg / ml. Exclusion Criteria: * The subject takes part in another study. * The subject is exclusion period determined by a previous study. * The subject is under judicial protection. * The subject or his representative refuses to sign the consent. * It is not possible to give the subject or his representative informed information. Non-inclusion criteria for those diseases or conditions associated (s) interfere (s): * The patient is pregnant or is breastfeeding. * The patient is already included in a surveillance program (PRADO, OSICAT). * Patient with a mechanical or biological mitral prosthesis. * History of mitral stenosis. * severe valvular surgery with maturity in months (\<30 days). * chronic renal impairment on dialysis. * High grade AV block (AVB and BAV3 2/1). * Hypertrophic cardiomyopathy. * Cardiogenic shock. * Contraindications to furosemide.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • CHU Arnaud de Villeneuve

    Montpellier, 34295, France

  • CHU Nimes

    Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.